

## Helicobacter pylori eradication experience with sequential treatment consisting of antibiotics which are used in conventional triple therapy

Serdar Olt<sup>1</sup>, Mustafa Erhan Altunöz<sup>2</sup>, Selçuk Yaylaci<sup>3</sup>

<sup>1</sup>Department of Internal Medicine, Adýyaman University Medical, Turkey;

<sup>2</sup>Department of Gastroenterology, Kocaeli Daryca Farabi State Hospital, Turkey;

<sup>3</sup>Department of Internal Medicine, Rize Fýnýdklý State Hospital, Turkey.

**Corresponding author:** Serdar Olt, MD;

Address: Department of Internal Medicine, Adýyaman University, Medical Faculty, Turkey;

E-mail: serdarolt84@yahoo.com

### Abstract

**Aim:** We aimed to investigate the eradication rate of the sequential treatment using the antibiotics which are used in classic triple therapy.

**Methods:** Ninety-two non-ulcer dyspepsia patients with positive *Helicobacter pylori* were included in this study. The presence of *Helicobacter pylori* was detected by histopathological examination of the biopsy specimen taken from the antrum and corpus. Our *Helicobacter pylori* eradication treatment protocol was 30 mg lansoprazole twice daily and 1g amoxicillin three times daily were given to the patients in the first 7 days, in the second 7 days 30 mg lansoprazole twice daily, 500 mg clarithromycin twice daily and 1 g amoxicillin twice daily. Six weeks after the end of the treatment, all of the patients were re-evaluated for *Helicobacter pylori* eradication by the urea breath test. Eradication was considered to be successful in patients with negative urea breath test.

**Results:** Thirty-four patients (37%) were male and fifty-eight (63%) were female. Mean age of the patients was 44±14 years. *H pylori* was eradicated in 89.1% of the cases.

**Conclusion:** Our study demonstrated that the method of nitro-imidazole-free sequential treatment was found to be a more successful method than the classic triple therapy. Given the success rate of eradication, we suggest a sequential treatment that consists of the antibiotics used in classic therapy which may be an important option in the first-line treatment.

**Keywords:** conventional triple therapy, *Helicobacter Pylori* eradication, sequential therapy.

## Introduction

*H. pylori* infection is one of the most significant morbidity and mortality reasons worldwide. Non-ulcer dyspepsia, peptic ulcer and gastric MALT-lymphoma are the diseases associated with *H. pylori*, and eradication is recommended in these cases according to the recent guidelines published (1). In the literature, it is also reported to be associated with idiopathic thrombocytopenia and idiopathic iron deficiency (2,3). *H. pylori* infection is decreasing in developed countries, whereas it is detected at very high rates in developing countries and the disease is acquired through oral-fecal route. Low socio-economic status and education level, living in a crowded house-hold, drinking infected water are among the important risk factors that cause infection. Although *H. pylori* eradication is not a fully resolved issue, many studies provided regimens with higher rates of eradication success. Antibiotic resistance seems to be an important problem in the *H. pylori* eradication, and updating the treatment regimens with new studies constantly becomes a necessity. Serious decline in the rate of success with the classic triple therapy, in parallel with the increasing clarithromycin resistance all over the world, gave birth to other treatment regimens (4). The success rate of these have risen to >90% by the use of nitro-imidazole with the sequential treatment rather than Clarithromycin (5).

In this present study, we aimed to investigate the eradication rate of the sequential treatment using the antibiotics which are used in classic triple therapy.

## Methods

Ninety-two non-ulcer dyspepsia patients with positive *Helicobacter pylori* were included in the study. The presence of *Helicobacter pylori* was detected by histopathological examination of the biopsy specimen taken from the antrum and corpus. Our *Helicobacter pylori* eradication treatment protocol was 30 mg lansoprazole twice daily and 1 g amoxicillin three times daily were given to the patients in the first 7 days, in the second 7 days 30 mg lansoprazole twice daily, 500 mg clarithromycin twice daily and 1 g amoxicillin twice daily. Six weeks after the end of the treatment, all of the patients were re-evaluated for *Helicobacter pylori* eradication by the urea breath test. Eradication was considered to be successful in patients with negative urea breath test.

## Results and Discussion

The demographic data of the patients and the eradication success rates are shown in Table 1. Thirty-four patients (37%) were male and fifty-eight (63%) were female. Mean age of the patients was 44±14 years. *H. pylori* was eradicated in 89.1% of the cases.

**Table 1. The demographic features of the patients and the *H. pylori* eradication success rate**

<b>Variable (n=92)</b>	
<b>Age (mean ± standard deviation)</b>	44 ± 14 years
<b>Gender (Male/Female)</b>	34/58
<b><i>H. pylori</i> Eradication rate (n %)</b>	89.1%

There are studies indicating that the *H. pylori* eradication success may vary among ethnic groups (6). Although the eradication success rates with the classic triple therapy were reported as 80% approximately in the literature, this ratio is found

even lower in Turkey in recent years (7,8).

In conclusion, our study demonstrated that the method of nitro-imidazole-free sequential treatment was found to be a more successful method than the classic triple therapy. Given the success rate

of eradication, we suggest a sequential treatment that consists of the antibiotics used in classic

therapy, which may be an important option in the first-line treatment.

**Conflicts of interest:** None declared.

## References

1. Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, et al. "Cervia II Working Group Report 2006": Guidelines on diagnosis and treatment of *Helicobacter pylori* infection in Italy. *Dig Liver Dis* 2007;39:782-9.
2. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, et al. Effects of eradication of *Helicobacter pylori* infection in patients with immune thrombocytopenic purpura: a systematic review. *Blood* 2009;113:1231-40.
3. Huang X, Qu X, Yan W, Huang Y, Cai M, Hu B, et al. Iron deficiency anaemia can be improved after eradication of *Helicobacter pylori*. *Postgrad Med J* 2010;86:272-8.
4. Rizwan M, Fatima N, Alvi A. Epidemiology and pattern of antibiotic resistance in *Helicobacter pylori*: scenario from Saudi Arabia. *Saudi J Gastroenterol* 2014;20:212-8.
5. Zullo A, Rinaldi V, Winn S, Meddi P, Lionetti R, Hassan C, et al. A new highly effective short-term therapy schedule for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther* 2000;14:715-8.
6. Leong RW. Differences in peptic ulcer between the east and the west. *Gastroenterol Clin N Am* 2009;38:363-79.
7. Kadayifci A, Buyukhatipoglu H, Savas MC, Simsek I. Eradication of *Helicobacter pylori* with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. *Clin Ther* 2006;28:1960-6.
8. Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, et al. Low eradication rate of *Helicobacter pylori* with triple 7-14 days and quadruple therapy in Turkey. *World J Gastroenterol* 2004;10:668-71.